ArticleJournal of cardiovascular development and disease2026
Incidence, Predictors and Outcome of Vasoplegia After Left Ventricular Assist Device Implantation.
Article in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasoplegia after heart failure surgery has been associated with increased morbidity and mortality. The aim of this study was to evaluate the incidence and impact of postoperative vasoplegia in patients undergoing durable continuous flow left ventricular assist device implantation (cfLVAD).
methodsAll patients who underwent cfLVAD implantation were included in this analysis. Vasoplegia was defined as the need for norepinephrine ≥0.2 μg/kgBW/min and/or any vasopressin dose for ≥12 h starting within 72 h postoperatively without bleeding/pericardial tamponade requiring surgical revision. Endpoints included the incidence of vasoplegia and 30- and 90-day mortality. Cox proportional hazard model was used to assess the association between vasoplegia and mortality. Multivariate logistic regression analysis was performed to identify predictors of vasoplegia.
resultsBetween 08/2010 and 12/2023, 307 consecutive patients underwent durable cfLVAD implantation. Mean age was 58 ± 11 years. Of the patients, 94% were operated with cardiopulmonary bypass and in 71% intraoperative hemoadsorption was applied. The incidence of vasoplegia was 23%. Vasoplegia was significantly associated with increased short-term mortality compared to non-vasoplegic patients (HR: CI:
conclusionVasoplegia after durable cfLVAD implantation is a common and serious complication associated with increased short-term mortality. Preoperative mechanical ventilation and vasopressor support are risk factors for developing postoperative vasoplegia. Intraoperative hemoadsorption appears to reduce the risk of vasoplegia after durable cfLVAD implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.